INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE);UNIVERSITE DE MONTPELLIER;CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER
发明人:
Jérôme MOREAUX,Bernard KLEIN
申请号：
US15127803
公开号：
US20170096710A1
申请日:
2015.03.20
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The present invention relates to a method of testing whether a patient suffering from multiple myeloma will respond or not to a combination treatment consisting of at least one histone deacetylase inhibitor (HDACi) with at least one DNA methyltransferase inhibitors (DNMTi) comprising: i) determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HADMS score trough the following formula (I) wherein βi represent the regression β coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=−1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score HADMS determined at step iii) with a predetermined reference value HADMSR v) and concluding that the patient will respond to the combination treatment when the HADMS score is higher than the predetermined reference value HADMSR or concluding that the patient will not respond to the combination treatment when the HADMS score is lower than the predetermined reference value HADMSR.
